Fulgent Genetic (NASDAQ:FLGT)‘s stock had its “buy” rating reiterated by research analysts at Piper Jaffray Companies in a research report issued to clients and investors on Tuesday.

Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Fulgent Genetic from a “sell” rating to a “hold” rating in a research report on Monday, October 9th. ValuEngine upgraded Fulgent Genetic from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. Finally, Credit Suisse Group reduced their price objective on Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, August 8th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $10.67.

Shares of Fulgent Genetic (NASDAQ FLGT) traded up 4.53% during mid-day trading on Tuesday, reaching $3.92. 32,144 shares of the company traded hands. Fulgent Genetic has a 52-week low of $3.60 and a 52-week high of $13.90. The company’s 50 day moving average is $4.62 and its 200 day moving average is $4.62. The stock’s market capitalization is $69.54 million.

Fulgent Genetic (NASDAQ:FLGT) last released its quarterly earnings data on Monday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.02. Fulgent Genetic had a negative return on equity of 0.02% and a negative net margin of 0.42%. The business had revenue of $4.64 million during the quarter, compared to analyst estimates of $5.03 million. On average, equities analysts forecast that Fulgent Genetic will post $0.14 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Fulgent Genetic (FLGT) Earns Buy Rating from Piper Jaffray Companies” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/24/fulgent-genetic-flgt-earns-buy-rating-from-piper-jaffray-companies.html.

In other Fulgent Genetic news, CFO Paul Kim sold 6,134 shares of the business’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $5.71, for a total transaction of $35,025.14. Following the completion of the transaction, the chief financial officer now owns 388,602 shares in the company, valued at approximately $2,218,917.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 58.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN boosted its position in Fulgent Genetic by 2,046.0% during the 1st quarter. Wells Fargo & Company MN now owns 10,730 shares of the company’s stock worth $118,000 after acquiring an additional 10,230 shares during the period. Bank of New York Mellon Corp acquired a new position in Fulgent Genetic during the 1st quarter worth $122,000. Finally, William Blair Investment Management LLC boosted its position in Fulgent Genetic by 10.4% during the 2nd quarter. William Blair Investment Management LLC now owns 640,219 shares of the company’s stock worth $4,091,000 after acquiring an additional 60,508 shares during the period. Institutional investors own 16.78% of the company’s stock.

About Fulgent Genetic

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.